Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook




 

Gene mutation melanoma drug recommended for NHS use

05 November 2012

By Maria Sheppard

Appeared in BioNews 680

A drug which prolongs life in a form of skin cancer associated with a genetic mutation has been recommended for use on the NHS.

The final draft guidance published by the National Institute for Health and Clinical Excellence (NICE) recommends the drug, vemurafenib, as well as another melanoma treatment, ipilimumab, despite both medicines having been rejected as insufficiently cost-effective last year. Following this, the manufacturers submitted extra data to NICE and agreed to reduce the price of the drugs, leading to the current recommendations.

Although neither drug is a cure for melanoma, both are expected to increase the quality of life and prolong life expectancy by several months for people with advanced forms of the condition.

'Advanced melanoma can significantly affect patients' quality of life and without effective new therapies, the prognosis for advanced disease is very poor', said Professor Carole Longson of NICE. 'Vemurafenib and ipilimumab are breakthrough treatments that can potentially significantly affect prognosis for these patients'.

Vemurafenib targets a genetic mutation, called BRAF V600, present in about half of all melanoma patients. Professor Alan Ashworth of the Institute of Cancer Research, London, who was involved in research into the drug, told the Telegraph the drug was 'a brilliant example of what new-generation targeted cancer therapies can achieve'.

The Guardian says that drugs targeted against gene-specific disease variants 'were expected to transform the prospects of cancer patients' but a recent World Oncology Forum highlighted that such high expectations were not being met. 'Drugs like vemurafenib', the newspaper relates, 'cleared the cancer in an apparently miraculous fashion, but it returned within months'.

As such, vemurafenib is recommended as an end-of-life treatment, and only around 1,000 people per year are expected to be suitable to receive it. The drug originally cost £52,500 for seven months but after NICE's initial decision not to recommend the drug, Roche, the manufacturer, offered a discount. 'The size of the discount is commercial-in-confidence', a statement from NICE relates.

Professor Peter Johnson, chief clinician of Cancer Research UK told the Guardian that the negotiations were 'a good example of NICE and the pharmaceutical companies working together to ensure that effective cancer treatments get from research to the patients who need them'.

SOURCES & REFERENCES
Mail Online | 02 November 2012
 
Telegraph | 02 November 2012
 
National Institute for Health and Clinical Excellence (press release) | 01 November 2012
 
Guardian | 02 November 2012
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

08 February 2016 - by Helen Robertson 
Researchers have visualised the onset of skin cancer at its earliest, single-cell stage for the first time...
16 November 2015 - by Meetal Solanki 
Researchers in the USA have mapped the sequence of genetic changes from early skin lesions, such as common moles, to malignant skin cancer...
02 November 2015 - by Arit Udoh 
The US Food and Drug Administration has approved a drug derived from a genetically modified herpes virus for the treatment of melanoma that cannot be removed by surgery...
24 August 2015 - by Kirsty Oswald 
Researchers have shown that a skin cancer drug can be used to treat advanced lung cancer in patients whose tumours harbour a particular mutation...
13 April 2015 - by Dr Nicoletta Charolidi 
A new type of cancer vaccine that enriches the immune system with tailor-made anti-tumour antibodies has shown early signs of promise...

27 February 2012 - by Dr Louisa Petchey 
The European approval of a new gene-specific drug for an aggressive form of skin cancer marks another step towards an era of personalised medicine. A recent trial showed promising results, with the drug shrinking tumour size and extending life span...
28 September 2009 - by Lorna Stewart 
An early stage trial of a new drug has given hope to skin cancer patients. The phase I trial, the results of which were presented at the European Cancer Organisation and the European Society for Medical Oncology conferences in Berlin, tested the drug PLX4032 for the treatment of advanced metastatic melanoma....
08 June 2009 - by Dr Will Fletcher 
A new 'personalised' drug has been found to decrease the size of tumours in patients with advanced melanoma by 30 per cent. Results of an initial trial were presented at the meeting of the American Society of Clinical Oncology in Orlando, US. The results showed that the experimental treatment, a 'personalised' oral drug known as PLX4032, kept the melanoma at bay for six months. Pharmaceutical giant Roche and a privately owned company called Plexxikon Inc will carry out larger trials later thi...
14 April 2009 - by Dr Will Fletcher 
Up to 70 per cent of cases of malignant melanoma, the most deadly form of skin cancer, may be triggered by a mutation in the BRAF gene caused by ageing and over-exposure to the sun. Details of the new findings were published in the journal Cancer Cell...
04 September 2006 - by Dr Jess Buxton 
By Dr Jess Buxton: US scientists have reported the first successful use of gene therapy to treat cancer. Two men with advanced melanoma are now free of the disease, after taking part in a trial based at the National Cancer Institute in Bethesda, Maryland. The new technique involves injecting patients...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust
Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation